REGULATORY

• New HIV Cases Reported in 2022 Hit 20-Year Low
  August 21, 2023

• MOF Budget Examiner Eager to Reshuffle Resources for Patented Drugs, LLPs
  August 21, 2023

• MEXT Pushes Joint Negotiations for Drug Purchases at University Hospitals
  August 17, 2023

• GSK’s Arexvy, 1st RSV Vaccine, Up for Japan Panel Review on Aug. 28
  August 16, 2023

• Govt to Properly Discuss Public Funding for COVID Drugs after October: Minister
  August 16, 2023

• Japan OKs 1st DPP-4 Generic for Januvia, Zytiga Draws 6 Entrants towards December Listing
  August 16, 2023

• Entries into Generic Business Should Be Regulated by Law: LDP Lawmaker
  August 10, 2023

• Japan Panel OKs Rollout of XBB.1.5-Based COVID Vaccines on Sept. 20
  August 10, 2023

• Japan’s Pandemic Response Agency Officially Set to Launch on September 1
  August 10, 2023

• Japan Sees Delay in Pilot-Based Revenue Assurance System for Antibiotics, Criteria Still Up in Air
  August 9, 2023

• MHLW Panel OKs Online Sales of Behind-the-Counter Drugs, but with Pharmacists’ Online Supervision
  August 9, 2023

• Approve 16 Pediatric Cancer Meds as Exceptional Step Beyond Law, Oncologist Urges
  August 8, 2023

• Novartis’ siRNA Dyslipidemia Therapy and More Up for Panel Review on August 21
  August 8, 2023

• MHLW Panel to Review Alzheimer’s Med Lecanemab on August 21
  August 8, 2023

• Japan Adopts New Evaluation Method for Nitrosamine Impurities Risks
  August 7, 2023

• Japan’s Healthcare Spending Up 11.0% in FY2021: IPSS Report
  August 7, 2023

• Despite Increase in Reviewers, Japan Faces Backlog of Over 4,000 Health Damage Claims for COVID Jabs
  August 4, 2023

• With Generics Now in Common Use, It’s Time for Debate on LLP Copay: Payers
  August 4, 2023

• Japan to Set Up New Forum on Dementia Measures: PM
  August 4, 2023

• 30% of Eligible Population Unaware of HPV Vaccine: Survey
  August 4, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 81
• 82
• 83
• 84
• 85
• 86
• 87
• 88
• 89
• …
• Next ›
• 最終 »